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Cutting Funds for Oral Contraceptives:
Violation of Equal Protection Rights and the Disparate
Impact on Women’s Healthcare
By
Rachel V. Rose*

Introduction
Cutting funding for oral contraceptives has far reaching
implications for women, including adverse impacts on women’s
health, negative economic impacts on society, and constitutional violations. In a country whose governmental health plans
(Medicare and Medicaid) reimburse men’s costs for Viagra®,1 it
is hardly appropriate to deny women access to prescribed oral
contraceptives that have traditionally been defined as supplementary services falling under the umbrella of primary care.2 Due
to the wording of a provision within the Deficit Reduction Act
of 2005, some contend that non-profit clinics and campus health
centers can no longer offer oral contraceptives at reduced rates.3
This article will show how decreasing funding for oral contraceptives violates equal protection and embodies a disparate impact
in relation to women’s health for Medicaid and Title X beneficiaries—low-income Americans who would benefit from access to
contraceptives and other preventative health-care services.
Part I of this article addresses the history, uses, and economics of oral contraceptives. Part II highlights the government’s
role and policies in funding oral contraceptives over the past 35
years. Part III discusses the present regulatory landscape, including The Deficit Reduction Act of 2005 (“DRA”), the Department
of Health and Human Services (“DHHS”) proposed regulations,
Prevention Through Affordable Access Act, and Title X. Finally,
Part IV shows how the history, politics, and regulations culminate
in a violation of the Constitutional right to equal protection.

I. Oral Contraceptives: History,
Uses, Economics
A. History
Oral contraceptives are relatively recent forms of contraception.4 Between 1950 and 1954, Gregory Pincos, a scientist,
and John Rock, a renowned Harvard obstetrician and gynecologist, developed a chemical contraceptive and performed the first
human clinical trial.5 The “Pill” regime that they established (21
days on progesterone to inhibit ovulation, 7 days to menstruate)
is still in use today.6 The “Pill,” called Enovid, was approved by
the United States Food and Drug Administration (“FDA”) for the
treatment of severe menstrual disorders.7
In the 1960’s, the FDA approved the first oral birth control pill.8 The FDA required Searle pharmaceutical company
to complete field trials for all doses of its oral contraceptive,
Enovid.9 Ortho Pharmaceutical introduced its first oral contraceptive in 1963. By 1965 the “Pill” became the leading method
of pre-conceptual and reversible contraception in the United
States.10
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During the 1970’s, United States Senator Gaylord
Nelson convened Senate hearings on the safety of the “Pill.”11
The FDA ordered that all oral contraceptive packages contain
information detailing possible side effects.12 By 1988, the FDA
recognized additional potential benefits of oral contraceptives,
including decreased incidence of the following: ovarian cancer,
endometrial cancer, pelvic inflammatory disease, ovarian cysts,
and benign breast disease.13
In the twenty years since the FDA recognized additional
potential benefits of oral contraceptives, manufacturers have
received FDA approval to use oral contraceptives for the treatment of acne and for the severe condition of premenstrual dysmorphic disorder (“PMDD”).14 Oral contraceptives have been
used to treat a variety of conditions and are proven to positively
affect many aspects of women’s health, including preserving
fertility.

B. Uses and Benefits of Birth Control Pills
Over the past 50 years, the FDA has recognized potential benefits in the area of women’s health, such as decreased
incidence of the following: ovarian cancer, endometrial cancer,
pelvic inflammatory disease, ovarian cysts, mid-cycle pain (dysmenorea), heavy bleeding and benign breast disease.15 Manufacturers have also received FDA approval to distribute oral
contraceptives for the treatment of acne and for PMDD.16 Physicians regularly prescribe oral contraceptives for other debilitating conditions such as polycystic ovarian syndrome (“PCOS”),
and endometriosis.17 These conditions, as well as PMDD, may
cause irregular menstrual cycles, increased risk of high blood
pressure, diabetes, high cholesterol, and infertility. These physical and emotional conditions may be mitigated by taking oral
contraceptives, which are proven to preserve fertility.
One of the most threatening conditions to a woman’s
fertility is endometriosis, a condition in which deposits of endometrium (uterine lining) are found outside the uterus.18 It is a
common disorder, yet it is one of the most enigmatic gynecologic
diseases.19 Endometriosis occurs when endometrial tissue outside
the uterus responds to changes in hormones,20 breaking down and
bleeding like the lining of the uterus does during the menstrual
cycle.21 This breakdown of tissue often creates adhesions (scar
tissue), which causes tremendous pain and binds surrounding
organs together.22 Aside from surgery, the most common way to
control symptoms of endometriosis and shrink existing implants
is through the use of oral contraceptives.23
As indicated, the uses of oral contraceptives extend
far beyond the indication for contraception. Ironically, PMDD,
PCOS, and endometriosis have been shown to cause infertility.24
Oral contraceptives, however, have been shown to temper these
conditions enabling a woman to retain her reproductive abilities.25
23

C. The Economics of Birth Control

pharmaceutical companies providing covered outpatient drugs are
required to calculate and submit to CMS, is not affected by the
The present cost of oral contraceptives is high.26 The increase in customary portion of the new formula were directed
cost to society, however, of preventing college students and low- at how pharmacies would be reimbursed.46 The Office of the
income women from purchasing them at a reduced rate is even Inspector General (“OIG”) and the General Accounting Office
higher.27 In 2004, researchers estimated a net public savings of (“GAO”) found that this new formula may “result in reimburse$4.3 billion by clinics through averting 1.4 million unintended ments to pharmacies that are below pharmacy acquisition costs.”
pregnancies.28 This number does not include the costs of infertil- Specifically, the DRA of 2005 requires manufacturers to report
ity treatments or the cost to treat the escalation of other diseases AMP and Best Price to CMS on a monthly basis compared to the
(Type 2 diabetes and cardiovascular disease) not associated with previous quarterly basis and imposes several important changes
regarding AMP and Best Price calculations.47 However, the act
PMDD, PCOS, and endometriosis.29
Funding from Medicaid programs and Title X of the Pub- has a provision that extends the “exclusion of customary prompt
lic Health Service Act has helped millions of women maintain a pay discounts [to wholesalers].” 48 This means that the AMP is
not affected by the increase in customary
healthy reproductive life.30 In fact, almost
prompt pay wholesaler discounts.49 Thereseventeen million women in the United
Yet,
despite
these
health
fore, the language should have no effect
States utilized these publicly subsidized
services in 2002.31 The federal and state benefits and substantial savings, on pharmaceutical manufacturers ability
to continue providing oral contraceptives
governments spent a combined $1.26 bilthe government enacted a
to public health and campus health clinlion on reversible contraceptive services.32
provision that has forced
ics, because the prices these facilities pay
Yet, despite these health benefits and substantial savings, the government enacted a pharmaceutical companies to are not included in the AMP, Best Price, or
ceiling price calculations.
provision that has forced pharmaceutical
stop providing oral
Equally important is the limitation
companies to stop providing oral contracontraceptives at reduced rates. that certain entities will be excluded from
ceptives at reduced rates.33
the calculation of the AMP and the “rebate
At a time when demand for subsidized contraceptives has increased, public funding for family percentage” on which pharmaceutical companies base their profplanning clinics has stagnated.34 Exacerbating this situation is the its.50 These entities include those defined in section 340B(a)(4)
unwillingness of many pharmaceutical companies to continue to of the Public Health Service Act; intermediate facilities for the
provide oral contraceptives to the public system funded by Title mentally retarded; a State-owned or operated nursing facility;
X at a relatively low cost.35 This appears to be the result of the and any other entity determined by the Secretary of DHHS to be
2005 DRA revamping the average manufacturer price (“AMP”) a safety net provider.51 The Office of Pharmacy Affairs oversees
formula and altering the 340B drug-pricing program. The Omni- the 340B pricing program and its administration.52 Entities that
bus Reconciliation Act of 1990 established AMP and Best Price have been identified as qualifying 340B organizations under the
for use in the Medicaid program.36 Thereby, sales by a manufac- Social Security Act and the Public Health Services Act (“PHSA”)
turer of covered outpatient drugs below ten percent of AMP were include: federally-qualified health centers; a family planning
generally excluded from Best Price.37 In 1992, the 340B program project receiving a grant or contract under Section 1001 of the
that was created when the Public Health Services Act (“PHSA”) PHSA; and any entity receiving assistance under section 318 (42
was amended to require pharmaceutical manufacturers to provide USCS § 247c) (relating to the treatment of sexually transmitted
diseases).53
prescription drugs at reduced prices to “covered entities.” 38
Even if campus health centers do not qualify as 340B
Calculating pharmaceutical costs for a 340B program
is a semi-complex formula based on the AMP that is provided to organizations, the Secretary of DHHS has the discretion to deterthe Center for Medicare/Medicaid Services (“CMS”).39 AMP is mine what facilities qualify as safety net providers to which the
defined as “[t]he average price paid to manufacturers by wholesal- sales of drugs at nominal prices would be appropriate based upon
ers for drugs distributed to the retail pharmacy class of trade.” 40 four factors.54 The factors are: 1) facility or entity type; 2) the
The lowest price available from “the manufacturer to any whole- nature of the services provided; 3) the patient population served;
saler, retailer, provider, health maintenance organization, or non- and 4) the number of other facilities or entities eligible to purprofit or government entity, with some exceptions” is considered chase at nominal prices in the same service area.55 Based upon
the Best Price.41 Although Best Price is required to be reduced these criteria, it is reasonable for the Secretary to include campus
to account for price adjustments such as rebates and discounts, it health centers as qualifying entities.
By interpreting the language to mean a 340B qualidoes not include prices charged to certain federal purchasers.42
The two factors involved in calculating 340B price are the AMP fying facility does not include community health and college
and a “rebate percentage” (consideration of both the AMP and health centers as an exclusion when calculating the AMP and the
the Best Price reported to CMS).43 This calculation is the “ceil- “rebate percentage,” and interpreting the language that exempts
ing price” formula for brand name pharmaceuticals (AMP for the certain “safety net providers” to exclude family planning clinics;
previous month—15.1% discount off the AMP) considered by pharmaceutical manufacturers, including Organon, the maker of
Cyclessa® and Desogen® oral contraceptives, made an economic
CMS.44
Beginning in 2007, seemingly small language changes decision not to provide drugs at a discounted rate.56 Despite the
in the DRA impacted the calculation of AMP, Best Price, and company being unhappy about increasing the prices for colleges,
limited the number of facilities that qualify for discounted “Nick Hart, Organon’s executive director of contraception, says
prices on birth control.45 The concerns over that the AMP, which they were forced to make ‘a business decision’ after the law went
24
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into effect.” 57 As a result, women who were paying between
$3–$10 per month for oral contraceptives are now paying nearly
900% more for the same prescription.58
Sadly, this price increase was unnecessary. The decision of pharmaceutical companies to stop offering low-priced
oral contraceptives to health centers and clinics was an independent decision that the DRA of 2005 did not mandate.59 On
the contrary, four types of entities, including 340B qualifying
facilities and certain safety net providers determined by the Secretary of DHHS, were excluded from the best price determination (meaning that pharmaceuticals offered at reduced rates to
these four types of entities would not be included in the price
determination).60 Additionally, Congress passed a provision to
delay the application of new payment limits for multiple source
drugs under Medicaid until September 30, 2009.61 Therefore, the
AMP or the “ceiling price” is not impacted by the DRA.62
Pharmaceutical companies’ interpretations of the DRA
of 2005 have affected over three million college and low-income
women.63 Many hard-working women can no longer access FDA
approved methods of birth control, including oral contraceptives.64 The only entities benefiting are manufacturers and savvy
entrepreneurs through higher prices and arbitrage opportunities.65
Overall, there is no logical explanation for repealing access to
low price oral contraceptives based on the statutory language of
the DRA of 2005.

II. Government Funding and Policies Related
to Oral Contraceptives

Under the Reagan Administration, public and nonprofit
entities encountered a setback in funding, in light of the conflicting interpretations of Title X equating oral contraception with
surgical abortions.75 However, the language, on its face, confirms
that the intent of Congress was not to equate the two.
In 1988, the Secretary of DHHS promulgated new regulations to differentiate between Title X programs and abortions,76
emphasizing that “the purpose and the demonstrated effect of contraceptive counseling is to promote the use of contraception.” 77
Unfortunately, DHHS also adopted regulations (the “Gag Rule”)
prohibiting Title X facilities from providing information, counseling, or referrals concerning abortions.78 During the first 18
years of the Title X program, the Act was interpreted to mean that
the funds could not be used to perform abortions, but it did not
restrict the ability of clinics to provide counseling or referrals.79
In 1991, the Supreme Court stipulated that, by clearly
defining “family planning,” the regulations clarify that Congress
intended Title X funds to be expended to support preventive family planning services.80 According to the General Accounting
Office, the majority of clients of Title X-sponsored clinics are not
pregnant and their services include and were restricted to physical examinations, education on contraceptive methods, preconceptional counseling, and general reproductive healthcare.81 The
Clinton Administration recognized that, while abortions are not a
method of family planning, the “Gag Rule” endangered women’s
lives and health by preventing them from receiving accurate medical information from their physicians.82 Consequently, the “Gag
Rule” was repealed.83

It is hard to fathom that President Dwight Eisenhower
III. The Present Regulatory Landscape’s
stated in 1959 that birth control “is not a proper political or govRole in the Crisis
ernment activity or function or responsibility” and emphatically
added that it is “not our business.” 66 Only five years later, PresiWithout publicly funded clinics providing contraceptive
dent Lyndon B. Johnson pushed legislation for federal support services, there would be 1.4 million more unintended pregnanof birth control for the poor.67 During the Nixon administration, cies and 49% more abortions annually in the United States.84
this trend continued.68 Title X of the PubMoreover, for every $1.00 spent to provide
lic Health Services Act (“Family Planning
services in the nationwide network of pubWithout publicly funded
Services and Population Research Act of
licly funded clinics, $4.02 is saved in Med1970”) authorized the Secretary to make clinics providing contraceptive icaid birth costs.85
grants to and enter into contracts with pubUnfortunately, the pharmaceutiservices, there would be
lic or nonprofit private entities to assist in
cal companies’ unwillingness to offer oral
the establishment and operation of volun- 1.4 million more unintended contraceptives at nominal prices to publicly
tary family planning projects, appropriat- pregnancies and 49% more funded clinics has created a birth control cri86
ing $180 million between 1971 and 1973.69
abortions annually in the sis. Now, millions of women are paying up
The only method of birth control not
to nine or ten times what they were paying
United States.
entitled to funds was a surgical abortion
before, if they can afford it.87 The compabecause it was not considered a preventive
nies’ decisions undermine the benefits under
family planning service.70 Under the Ford Administration, Con- Title X and are detrimental individually on women’s reproductive
gress extended grants for comprehensive public health services71 health and collectively on our nation’s economic welfare.88
and expressly defined “community health centers” as entities that
provide primary health services and referrals to providers of supA. Title X v. DRA
plementary health services.72 Primary health services included
Statutes or provisions relating to the same individual
family planning, and supplemental health services included pharmaceutical and health education services.73 The Secretary could or class of individuals, or to a closely allied subject or object
89
“make grants to public and nonprofit private entities for projects may be regarded under the rule of in pari materia, to ascerto plan and develop community health centers which will serve tain and effectuate Congressional intent by proceeding upon the
medically underserved populations.” 74 Clearly, there was a com- supposition that several statutes were governed by one spirit and
90
mitment to ensure that women received the care and treatment policy and were intended to be consistent and harmonious.
In the present case, Title X and section 6001 of the DRA, both
they needed to preserve their reproductive health.
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provisions related to funding, should be read together for the
intent of providing funding so all women could have access to
reproductive healthcare, family planning, and preconceptional
birth control.91

1. Title X: Settled Policy
Since 1970, the purpose of Title X has been to assist in
making voluntary family planning services available to all persons by enabling public and non-profit private entities to plan and
develop comprehensive programs. Understanding the need for a
high standard for ethical delivery of services, Title X required
that clients be offered a broad range of contraceptive methods.92
Today, Title X supports approximately 4,400 out of 7,700 family
planning clinics, serving nearly five million women.93 The current guidelines were developed in conjunction with the American
College of Obstetricians and Gynecologist (“ACOG”) and require
a complete physical exam (including Pap test) and education
about the importance of preventive care.94 Title X is indicative
of settled policy that women should have access to reproductive
healthcare, family planning, and preconceptional birth control.

2. 2005 DRA – Effective January 2007
An unintended consequence of the DRA, specifically
Section 6001, is that health centers no longer receive prescription
contraceptives at a nominal or base price. Because there is a provision in the DRA that insulated publicly funded health clinics
from paying a higher premium and in turn exempted these prices
from the AMP calculations, there is no acceptable explanation
for this consequence. The only explanation proffered by the pharmaceutical companies is that they made a “business decision” to
no longer follow established legislative precedent. Furthermore,
Congress has done nothing since the implementation of the DRA
to rectify the situation. The result is that the objective of Title X
and Medicaid is being undermined while pharmaceutical manufacturers are realizing higher profit margins.
The provisions in section 6001 of the DRA should be
construed to mean that because of the “safe harbor” exempting
nominal sales pricing to certain entities from being included in
the calculation, Congress intended to preserve the Title X objective, while not adversely impacting the reimbursement of pharmaceuticals through Medicaid. It is imperative that Congress
continue to uphold the original legislative intent of providing
access to high quality contraceptive services and preventive care
to young and low-income citizens.95

B. DHHS Initiatives to Undermine Women’s
Reproductive Healthcare Funding
In the summer of 2008, the Bush Administration called
on DHHS to draft new rules that would severely restrict women’s
healthcare options by defining “abortion” so broadly that it would
encompass many types of birth control, including oral contraceptives.96 The DHHS proposal defined abortion as “any of the
various procedures—including the prescription, dispensing and
administration of any drug or the performance of any procedure
or any other action—that results in the termination of the life of
a human being in utero between conception and natural birth,
whether before or after implantation.” 97 This definition defies
26

Congressional intent and the Supreme Court’s interpretation of
abortion.98
In addition to posing serious threats to the reproductive
health of millions of uninsured and low-income Americans, the
language could prevent health facilities from guaranteeing their
patients access to the full range of comprehensive reproductive
healthcare.99 On July 15, 2008, several Senators signed a letter
addressed to the Secretary of DHHS urging reconsideration of
the regulations.100 One argument was that the proposed definition would allow common forms of contraception such as the
birth control pill to be classified as abortion, thereby denying
contraception to women who need it.”101 In a follow-up letter,
they emphasized the medical definition of pregnancy,102 specifically that a pregnancy does not begin until a fertilized egg
implants itself to the uterine wall,103 and most modern forms of
birth control work by blocking implantation.104 Calling a preimplanted fertilized egg a “human being in utero” is incorrect.105
Ultimately, confusing the definitions of contraception and abortion would wreak havoc on law, regulations, and policy.106

C. Prevention Through Affordable Access Act
The Prevention Through Affordable Access Act was
introduced in the House of Representatives107 to clarify any ambiguity in the DRA language and protect student health centers and
public or nonprofit private entities providing health services.108
It received bipartisan support and aimed to “rectify an allegedly
flawed condition in the DRA, which caused national pharmaceutical companies to stop selling birth control to college clinics [and
publicly funded health clinics] at discounted prices.”109 Both the
House and the Senate versions of the bill were introduced and
referred to Committees nearly a year ago.110 No other action has
been taken since the initial introduction.111

IV. The 2005 DRA – Violation of Equal
Protection
In December 1961, it was still a crime to use birth control in Connecticut.112 Boldly, C. Lee Buxton, M.D. and Estelle
Griswold opened four Planned Parenthood Clinics.113 Their arrest
brought national attention to anachronistic state laws, which culminated in a 7–2 ruling by the United State Supreme Court that
Connecticut’s law prohibiting the use of birth control was unconstitutional, violating a couple’s right to privacy.114 Eisenstadt v.
Baird made it clear that a state cannot impede the distribution of
birth control to an unmarried person, thus striking down a Massachusetts law.115 Less than a year later, the Supreme Court ruled
on one of the most controversial issues of our time—abortion.116
These judicial precedents not only set the tone for the adoption
of Title X, but also laid the foundation for recognizing women as
a protected class.

A. Equal Protection Analysis
The fundamental question under consideration is
whether there is something in the DRA requiring pharmaceutical
companies to no longer offer nominal pricing on oral contraceptives to public, non-profit, and campus health clinics. The Equal
Protection Clause of the United States Constitution provides
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that no person shall be denied the equal protection of the law.117
When assessing a statute under an intermediate scruFundamentally, equal protection deals with “governmental clas- tiny level of review, two operative parts must be considered—
sifications that deprive a certain class of persons of benefits that the “means” and the “ends.”130 The “ends” or the objective the
persons in other classes are entitled to receive, or that subject government seeks to achieve must be actual and important. The
a certain class of persons to burdens that are not imposed on “means” or the classification the government has used must be
persons in other classes.”118 By making oral contraceptives “substantially related” to the ends. Here, the means (the genderunavailable because of the exorbitant cost, women are the class based reproductive health access exclusion) and the ends (preof persons being deprived of benefits of reproductive healthcare sumably, reducing Medicaid spending by $4.7 billion between
and family planning they are entitled to under Medicaid and Title 2006–2010) can be compared to United States v. Virginia, where
X.119 Although men also use the same federally funded centers, the Supreme Court subjected Virginia Military Institute’s (“VMI”)
they do not carry the burden of paying more for prescriptions male-only admissions policy to intermediate scrutiny.131
under the DRA.
The Court determined that Virginia’s male-only admisOn its face, the DRA does not discriminate because it sions policy to VMI was not “substantially related” to the
contains no explicit gender classification language.120 However, state’s objective of maintaining the adversative method, and the
just because it is facially neutral does not mean it is free from dis- objective of educating “citizen soldiers” was not “substantially
crimination. The difference is that courts will not merely assume advanced by women’s categorical exclusion, in total disregard
that the DRA is intentionally discriminatory; instead, evidence of their individual merit.”132 Likewise, the federal government’s
of discrimination must be found through its administration and gender-based reproductive health access exclusion in the DRA
purpose or effect.121 In Yick Wo v. Hopkins, the Supreme Court is not “substantially related” to the objective of spending reducheld that even if a law “be fair on its face and impartial in its tion. For every tax dollar spent on contraceptive services, $3.00
appearance, [equal protection will still be violated] if it is applied in Medicaid costs for pregnancy-related healthcare and medical
and administered by public authority with an evil eye and an care of newborns is saved, 1.3 million unplanned pregnancies are
unequal hand.”122 There, equal protection was denied when the avoided, and without publicly supported services, there would be
discrimination and public administration of the law was found an annual increase of 40% more abortions.133 Furthermore, the
to be illegal.
DRA defies the purpose of other statutes, Title X and Medicaid,
Personnel Administrator of Massachusetts v. Feeney which have ensured women’s affordable access to oral contracepdealt with discriminatory intent in the purpose and effect of a law tives in relation to reproductive health and family planning for
giving preferential treatment to veterans.123 There, the Supreme over a quarter of a century. When a heightened level of scrutiny is
Court asserted that proof of discriminatory “impact provides ‘an applied, economic reasons are not enough to uphold a statute as
important starting point,’ but purposeful discrimination is the constitutional. Therefore, in terms of the DRA, the government
condition that offends the Constitution.”124
has failed to demonstrate the requisite “exceedingly persuasive
The DRA must be considered in pari materia with Title justification” for denying women access to affordable oral conX and Medicaid when considering the administration and pur- traceptives to which they are entitled under federal law.134
pose and effect of the law. The situation of women being denied
A final step in the “means/ends” analysis is the assessaccess to affordable oral contraceptives because of the AMP cal- ment of the concepts of over-inclusiveness and under-inclusiveculation is akin to the situation in Yick Wo and distinguishable ness. A law is over-inclusive when it applies to some situations
from Feeney. In fiscal year 2006, the Medicaid program spent that do not serve its objectives.135 Conversely, a law is under$1.3 billion for family planning services, and Title X funds con- inclusive when it “does not apply to some situations that do serve
tributed $215 million to approximately 7,683 clinics.125 Each its objectives.”136 The DRA, although it contains no express
year, approximately seven million women received contracep- language regarding gender differentiation and denial of access
tive services.126 Of the total number of
to oral contraceptives, can be seen as overpatients treated, men accounted for only
inclusive because it affects all women procur5% of the overall caseload.127 Here, As a matter of public policy, ing oral contraceptives from federally funded or
Congressional intent points toward we, as a nation, want women campus health clinics, including those individuthe “evil eye and unequal hand” and to have affordable access to als not traditionally covered under the umbrella
of Title X or Medicaid. There is a strong likeli“purposeful discrimination” because
oral contraceptives.
hood that the classification will meet the appliCongress knew the DRA AMP formula
cable means test.
was being applied in a way that denied
As a matter of public policy, we, as a nation, want women
women access to oral contraceptives to which they were entitled
under federal programs.128 Congress also knew of executive ini- to have affordable access to oral contraceptives. As a plurality
tiatives to equate oral contraceptives to a surgical abortion.129 of the Supreme Court acknowledged 35 years ago, “our Nation
Therefore, the discrimination against women, public administra- has had a long and unfortunate history of sex discrimination.”137
tion, and purpose and effect of the DRA should be violations of Public policy has been defined as “the principle of law which
equal protection.
holds that no citizen can lawfully do that which has a tendency
For purposes of the DRA, the classifying factor distin- to be injurious to the public or against the public good.”138 Preguishing between two similarly situated classes is gender, which venting access to oral contraceptives for the treatment of medireceives intermediate scrutiny. Men’s access to prescriptions cal conditions that inhibit women from being productive and
related to reproductive health has not been rendered inaccessible efficient citizens, for family planning purposes, which in turn
due to cost while women’s prescriptions for oral contraceptives decreases abortion rates and government costs, and for discouraghave been affected by the DRA.
ing healthy living at every stage of life are acts that are injurious
Spring 2009
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to the public good.139 Therefore, as a matter of public policy, it is
imperative that access to oral contraceptives at pre-DRA prices
be reinstated.

B. Remedies
The Supreme Court has held that 42 U.S.C. § 1983
broadly construes a private federal right of action for damages
and injunctive relief to redress violations by state officials of
rights created by the United States Constitution as well as federal
statutes.140 For example, a reading of the Public Health Service
Act does not “reveal a precise or elaborate remedial scheme that
would be obfuscated by allowing enforcement through a § 1983
action.”141 Also, the statutory language and legislative history
indicate an intent to improve and expand all aspects of family
planning services by providing grants to public or nonprofit private entities or state health authorities.142 Therefore, the Court in
Planned Parenthood of Billings v. Montana concluded that the
Public Health Services Act created federally enforceable rights
in the plaintiffs and since no Congressional intent to preclude
private enforcement existed, § 1983 provided a cause of action to
remedy an alleged violation of the Act.143
Relying on Supreme Court decisions, a U.S. District
Court recently held in Children’s Hosp. of Philadelphia v.
Horizon NJ Health that a hospital’s claims against an insurance
provider for deprivation of constitutional rights in violation of 42
U.S.C. § 1983 could proceed.144 The court noted that a symbiotic
relationship was present because approximately 50% of funding
received was federal and that the insurance company derived a
substantial benefit.145 Additionally, the doctrine of third party
standing and in turn associational standing was upheld because
“the hospital had alleged facts sufficient to establish the thirdparty standing of its doctors to bring their patients’ claims.”146
Similarly, the DRA, because it is read in pari materia
with Title X and Medicaid, creates federally enforceable rights
in women who utilize clinics that qualify for federal funding
and since no Congressional intent is presently precluding private enforcement, § 1983 should be applicable. As in Children’s
Hosp. of Philadelphia, a symbiotic relationship exists between
the government and the pharmaceutical companies because the

drug manufacturers derive a substantial benefit from the billions
of dollars the government expends annually on prescriptions.147
In addition, Congress knew of the denial of access to oral contraceptives and has not passed any legislation or enforced correct
application of the AMP formula.148
The pharmaceutical companies’ interpretations of Section 6001 of the DRA to no longer offer oral contraceptives to
federally funded and campus health clinics based on the AMP
formula is also possibly unconstitutional. Federal courts have
held that private corporations that contract with the government
may not be entitled to qualified immunity under § 1983.149 The
Supreme Court, applying the nexus approach, held the appropriate inquiry is “whether there is a sufficiently close nexus between
the State and the challenged action of the regulated entity so that
the action of the latter may be fairly treated as that of the State
itself.”150
Moose Lodge No. 107 v. Irvis is an instructive example of
the application of the inquiry.151 Focusing on the state’s involvement, the challenged action was the lodge’s racial discrimination against private guests.152 The Supreme Court emphasized
that a nexus would exist and state action would be present, if the
state had “fostered or encouraged” the allegedly unconstitutional
action.153 Applying this reasoning to the DRA and the “business
decisions” made by pharmaceutical companies, it could be found
that a “sufficiently close nexus” between the State, the pharmaceutical companies and the potentially challenged action exists
to impose liability on both the State and the private companies
under § 1983.

Conclusion
There is no comparable situation for men. Women’s
overall healthcare is at issue and this type of funding reduction
of medical treatment options promulgated by the DRA is constitutionally invalid. As shown, cutting funding for oral contraceptives has far reaching implications for women including the
Deficit Reduction Act of 2005, which embodies the notion that
what is not good policy is also not good politics.
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